OPR - Delayed Quote • USD IMNM Oct 2024 22.500 call (IMNM241018C00022500) Follow 5.0000 0.0000 (0.00%) At close: April 10 at 12:38 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for IMNM241018C00022500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: IMNM Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for Immunome Appoints Sandra M. Swain to Board of Directors Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting New Strong Sell Stocks for April 4th Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions Immunome to Participate in the Leerink Partners Global Biopharma Conference Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
